A retrospective study identified ACSF2 as a sensitive and specific molecular marker of recurrent deep vein thrombosis by gene expression profiling for the first time, which makes great significance for selecting groups requiring extended anticoagulant therapy after confirmed in larger prospective studies (Montes et al., 2016). This evidence concerns the gene ACSF2 and deep vein thrombosis.